Sugi Predict

Sugi Predict / Compounds / SCHEMBL1305844

SCHEMBL1305844

SCHEMBL1305844

O=C(NC12CCC(C(=O)O)(CC1)CC2)OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 1/20 0.48
▸ CTSB P07858 1/20 0.48
▸ CTSS P25774 1/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ LMNA P02545 1/20 0.47
▸ CTRB1 P17538 2/20 0.46
▸ MGLL Q99685 1/20 0.46
▸ CA12 O43570 2/20 0.46
▸ CA1 P00915 2/20 0.46
▸ CA2 P00918 2/20 0.46
▸ CA9 Q16790 2/20 0.46
▸ ALDH1A1 P00352 3/20 0.45
▸ GAA P10253 1/20 0.45
▸ NPC1 O15118 2/20 0.44
▸ RAB9A P51151 2/20 0.44
▸ POLB P06746 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ TP53 P04637 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2826325 0.92 CTSL (0.46) CTSLCTSBCTSSSMN1; SMN2LMNA
SCHEMBL3941493 0.89 TSHR (0.47) CTSLCTSBCTSSSMN1; SMN2LMNA
SCHEMBL1305698 0.87 CHRM1 (0.50) CTSLCTSBCTSSSMN1; SMN2LMNA
SCHEMBL9951765 0.87 CTSS (0.46) CTSLCTSBCTSSSMN1; SMN2LMNA
SCHEMBL13085484 0.87 CTSL (0.49) CTSLCTSBCTSSSMN1; SMN2LMNA
SCHEMBL20564912 0.87 ALDH1A1 (0.49) CTSLCTSBCTSSSMN1; SMN2LMNA
SCHEMBL13085368 0.85 CTSL (0.48) CTSLCTSBCTSSSMN1; SMN2LMNA
SCHEMBL3931249 0.85 CTSL (0.48) CTSLCTSBCTSSSMN1; SMN2LMNA
SCHEMBL1308680 0.85 CTSL (0.46) CTSLCTSBCTSSSMN1; SMN2LMNA
SCHEMBL3923195 0.84 CTSL (0.47) CTSLCTSBCTSSSMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12583839-B2 PD-L1 antagonist compound ADLAI NORTYE BIOPHARMA CO., LTD. (CN) 2026-03-24 — — US disclosed
US-20230137932-A1 CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2 DANA-FARBER CANCER INSTITUTE, INC. 2023-05-04 — — US disclosed
US-20230054028-A1 PD-L1 ANTAGONIST COMPOUND ADLAI NORTYE BIOPHARMA CO., LTD. (CN) 2023-02-23 — — US disclosed
EP-4087571-A1 CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2 Dana-Farber Cancer Institute, Inc. (US) 2022-11-16 — — EP disclosed
EP-4083032-A1 PD-L1 ANTAGONIST COMPOUND Adlai Nortye Biopharma Co., Ltd. (CN) 2022-11-02 — — EP disclosed
CN-115279373-A Cyanopyrimidine inhibitors of EGFR/HER2 达纳-法伯癌症研究所股份有限公司 2022-11-01 — — CN disclosed
WO-2021129584-A1 PD-L1 ANTAGONIST COMPOUND 杭州阿诺生物医药科技有限公司 2021-07-01 — — WO disclosed
EP-1954287-B2 CETP INHIBITORS MERCK SHARP & DOHME (US) 2016-02-24 — — EP disclosed
EP-1719757-B1 BICYCLO DERIVATIVE KYORIN SEIYAKU KK (JP) 2013-10-09 — — EP disclosed
US-8507493-B2 Amide and amidine derivatives and uses thereof ABBVIE INC. (US) 2013-08-13 — — US disclosed
US-7560569-B2 (2S,4S)-1-[[(4-carbamoylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile, for treating type II diabetes; increase glucagon-like peptide activity KYORIN PHARMACEUTICAL CO., LTD (JP) 2009-07-14 — — US disclosed
US-7514571-B2 Bicyclo derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2009-04-07 — — US disclosed
EP-1954287-A2 CETP INHIBITORS Merck & Co., Inc. (US) 2008-08-13 — — EP disclosed
US-20080146818-A1 Dipeptidylpeptidase IV (DPP-IV) inhibitory activity; (2S,4S)-1-[[N-(4-ethoxycarbonylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile)); diabetes KYORIN PHARMACEUTICAL CO., LTD. (JP) 2008-06-19 — — US disclosed
US-20070265320-A1 Bicycloamide Derivative KYORIN PHARMACEUTICAL CO., LTD (JP) 2007-11-15 — — US disclosed
US-20070167501-A1 Bicyclo derivative KYORIN PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 — — US disclosed
WO-2007070173-A2 CETP INHIBITORS MERCK & CO., INC. (US) 2007-06-21 — — WO disclosed
EP-1719757-A1 BICYCLO DERIVATIVE Kyorin Pharmaceutical Co., Ltd. (JP) 2006-11-08 — — EP disclosed
EP-1717225-A1 BICYCLIC AMIDE DERIVATIVES Kyorin Pharmaceutical Co., Ltd. (JP) 2006-11-02 — — EP disclosed
EP-1712547-A1 BICYCLOESTER DERIVATIVE Kyorin Pharmaceutical Co., Ltd. (JP) 2006-10-18 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230054028-A1 PD-L1 ANTAGONIST COMPOUND CD274, PDCD1LG2, PDCD1 CTSL 652/4885CTSB 1897/4885CTSS 3755/4885
US-20230137932-A1 CYANO-PYRIMIDINE INHIBITORS OF EGFR/HER2 ERBB2, EGFR, ERBB3 CTSL 2082/4885CTSB 1529/4885CTSS 2327/4885
US-20070265320-A1 Bicycloamide Derivative DPP4, DPP7, DPP9 CTSL 459/4885CTSB 654/4885CTSS 849/4885
US-20070167501-A1 Bicyclo derivative DPP4, DPP7, DPP9 CTSL 810/4885CTSB 1103/4885CTSS 1596/4885
US-20080146818-A1 Dipeptidylpeptidase IV (DPP-IV) inhibitory activity; (2S,4S)-1-[[N-(4-ethoxycarbonylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile)); diabetes DPP4, DPP7, DPP3 CTSL 179/4885CTSB 392/4885CTSS 360/4885
US-12583839-B2 PD-L1 antagonist compound CD274, PDCD1LG2, PDCD1 CTSL 938/4885CTSB 2212/4885CTSS 3450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.